Kurt McCammon, MD
Urogynecology and Reconstructive Pelvic Surgery · Virginia Beach, VANPI 1598743692
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,050 of the $66,543 with a category attached, or 73.7%. Boston Scientific accounts for 80.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $37,179 and has fallen 98.6% since, to $503 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $384.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$54K
- AbbVie$10K
- Johnson & Johnson$510
- Axonics, Inc.$377
- Coloplast$220
- Astellas Pharma US Inc$205
- plus $2K from 18 others
Across 53 payments — averaging $2579.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$77K
- Endo Pharmaceuticals Inc.$41K
- Urovant Sciences Inc$9K
- Laborie Medical Technologies Corp.$7K
- Urotronic, Inc$3K
What the payments were for
- Consulting fees$1,5372%
- Speaking & faculty fees$49,05074%
- Grants$1250%
- Travel & lodging$11,61317%
- Food & beverage$4,0916%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 46 | $53,731 |
| AbbVie(2 entities) | 10 | $9,730 |
| Johnson & Johnson | 22 | $510 |
| Axonics, Inc. | 4 | $377 |
| Coloplast | 2 | $220 |
| Astellas Pharma US Inc | 12 | $205 |
| Bayer | 15 | $197 |
| Medtronic(2 entities) | 3 | $193 |
| C. R. Bard, Inc. & Subsidiaries | 7 | $153 |
| Neotract Inc. | 4 | $153 |
| Dendreon Pharmaceuticals LLC | 10 | $152 |
| Endo Pharmaceuticals Inc. | 10 | $144 |
| Innovation Technologies Inc | 1 | $142 |
| Pfizer | 8 | $129 |
| Calyxo, Inc. | 1 | $120 |
| KARL Storz Endoscopy-america | 1 | $114 |
| Olympus America Inc. | 4 | $62 |
| Ferring Pharmaceuticals Inc. | 4 | $56 |
| Travere Therapeutics, Inc. | 3 | $53 |
| Blue Earth Diagnostics | 2 | $37 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $20 |
| Teleflex LLC | 1 | $20 |
| Telix Pharmaceuticals | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$33,855
- ADVANCE$16,312
- BOTOX COSMETIC$9,379
- GENERAL - THERAPIES$2,429
- Axonics$316
- Bulkamid$171
- Irrisept$142
- SPEEDICATH$127
- BOTOX$125
- CVAC Aspiration System$120
- Flex-X$114
- INTERSTIM$105
How this compares
$66,543 in reported general payments places this provider in the 95th percentile of 29 urogynecology and reconstructive pelvic surgery providers in Virginia.
See all urogynecology and reconstructive pelvic surgery providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 36 | $28,628 |
| Trospium Chloride ErTrospium Chloride | 49 | $11,456 |
| Trospium Chloride | 39 | $3,631 |
| Tamsulosin Hcl | 76 | $1,133 |
| Estradiol | 20 | $767 |
| Solifenacin Succinate | 15 | $349 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $321 |
| Doxycycline Hyclate | 29 | $165 |
| Ciprofloxacin Hcl | 20 | $111 |
| Cephalexin | 15 | $60 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $205 | $28,62836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 urogynecology and reconstructive pelvic surgery providers in Virginia.
Other urogynecology and reconstructive pelvic surgery in Virginia Beach
- Katherine HinesVirginia Beach$4K
- Seyed ShobeiriFalls Church$116K
- Jeffrey WelgossAnnandale$50K
- Nathan GueretteMidlothian$20K
- Eric ChangStafford$11K
- Patricia MwesigwaArlington$8K
- Anna TrikhachevaPortsmouth$6K
- Walter von PechmannAnnandale$6K
- Mary BurnsViriginia Beach$6K
- Meghana GowdaRichmond$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.